



OPEN ACCESS

EDITED AND REVIEWED BY
Olumayokun Olajide,
University of Huddersfield,
United Kingdom

*CORRESPONDENCE
Xinting Pan,
✉ 0536pxt@163.com

RECEIVED 16 September 2023
ACCEPTED 18 October 2023
PUBLISHED 26 October 2023

CITATION

Yan X, Lin T, Zhu Q, Zhang Y, Song Z and Pan X (2023), Corrigendum: Naringenin protects against acute pancreatitis-associated intestinal injury by inhibiting NLRP3 inflammasome activation via AhR signaling. *Front. Pharmacol.* 14:1295494. doi: 10.3389/fphar.2023.1295494

COPYRIGHT

© 2023 Yan, Lin, Zhu, Zhang, Song and Pan. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Naringenin protects against acute pancreatitis-associated intestinal injury by inhibiting NLRP3 inflammasome activation via AhR signaling

Xu Yan, Tianjiao Lin, Qingyun Zhu, Yushi Zhang, Zhimin Song and Xinting Pan*

The Affiliated Hospital of Qingdao University, Qingdao, China

KEYWORDS

severe acute pancreatitis, intestinal injury, naringenin, AhR, NLRP3 inflammasome

A Corrigendum on

Naringenin protects against acute pancreatitis-associated intestinal injury by inhibiting NLRP3 inflammasome activation via AhR signaling

by Yan X, Lin T, Zhu Q, Zhang Y, Song Z and Pan X (2023). *Front. Pharmacol.* 14:1090261. doi: 10.3389/fphar.2023.1090261

In the published article, there was an error in [Figure 3](#) as published. The image of the DEX group in [Figure 3A](#) was inadvertently misused during the final assembly of [Figure 3](#). The corrected [Figure 3](#) and its caption are provided herein.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 3

Naringenin inhibits activation of the NLRP3 inflammasome. **(A)** Immunohistochemical staining was performed on ileum sections to detect NLRP3. **(B)** Relative expression levels of NLRP3 mRNA in the intestine, as analyzed by real-time PCR. **(C)** Western blot analysis of NLRP3 expression in the intestine of each group and corresponding grayscale statistics. ****p* < .0001 vs. NS; ###*p* < .0001 vs. SAP, ΔΔ*P*.